$Lipocine (LPCN.US)$ NEWS Lipocine Announces Positive LPCN 2...
NEWS
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine Inc. (NASDAQ: LPCN) announces positive results from a Phase 2 clinical trial for LPCN 2401, showing significant improvements in body composition. The treatment led to increased lean mass by 4.4% and decreased fat mass by 6.7%. Additionally, android fat decreased by 4.1% and bone mineral content increased by 2.8%. The treatment was well-tolerated, with adverse events similar to placebo. Results suggest the potential for LPCN 2401 to be used in combination with incretin mimetics or as a monotherapy post discontinuation, offering promising outcomes for weight management interventions.
Lipocine Inc. (NASDAQ: LPCN) announces positive results from a Phase 2 clinical trial for LPCN 2401, showing significant improvements in body composition. The treatment led to increased lean mass by 4.4% and decreased fat mass by 6.7%. Additionally, android fat decreased by 4.1% and bone mineral content increased by 2.8%. The treatment was well-tolerated, with adverse events similar to placebo. Results suggest the potential for LPCN 2401 to be used in combination with incretin mimetics or as a monotherapy post discontinuation, offering promising outcomes for weight management interventions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
505Followers
64Following
3175Visitors
Follow